Postpartum Hemorrhage

CARLSBAD, CA / ACCESSWIRE / January 15, 2025 / CB Therapeutics, a U.S.-based synthetic biology company known for its innovative bio-manufacturing solutions, today announced the expansion of its platform to include ergoline-based compounds. Ergolines-structurally related to alkaloids naturally found in ergot fungi-hold broad potential in areas ranging from neurological research and psychiatric applications to treatments for migraines, postpartum hemorrhage, and Parkinson\'s disease. Building on its proven precision fermentation platform, CB Therapeutics now offers a scalable, eco-conscious pathway for producing these high-value molecules with unmatched consistency and purity. While many recognize ergolines through their association with lysergic acid derivatives-including LSD-this diverse class of compounds has long been investigated for numerous medical and research applications. Traditional chemical synthesis methods or direct sourcing from ergot fungi can be dangerous, inefficient, environmentally burdensome, and difficult to standardize. By contrast, CB Therapeutics utilizes yeast-based precision fermentation to produce bioidentical ergoline compounds with minimal waste, reduced carbon footprint, and dependable yields at any scale.\"Our goal is to unlock nature\'s most promising compounds in the most sustainable way,\" said Sher Butt, MBA, Chief Executive Officer of CB Therapeutics. \"By adding ergolines to our synthetic biology platform, we\'re helping to accelerate research and commercialization pathways for partners who want to explore or develop new therapies in neurology, mental health, and beyond.\"\"Our precision fermentation platform can deliver consistent, pure compounds for use in translational research and product development. Our aim is to make these molecules more accessible and sustainable, ultimately broadening their potential impact.\" noted Jacob Vogan, PhD, Chief Scientific Officer at CB TherapeuticsKey Advantages of CB Therapeutics\' Biosynthesis Platform:Sustainable Production: Precision fermentation significantly reduces toxic byproducts and resource consumption compared to traditional extraction or chemical synthesis methods.Scalability & Consistency: From small research batches to large-scale manufacturing, the company\'s bioreactors and integrated processing systems ensure high quality precision fermentation batches.Broad Application Potential: Beyond psychedelic research (e.g., LSD derivatives), ergoline-related compounds show promise in treating migraines, supporting obstetric care, and exploring therapeutic avenues in neurology and psychiatry.Partnership Opportunities: CB Therapeutics actively seeks collaborations to accelerate product development in pharmaceuticals, clinical research, and other emerging markets worldwide.For more information on partnership, licensing, or collaboration inquiries, please contact [email protected]About CB TherapeuticsCB Therapeutics is a U.S.-based synthetic biology company focused on tackling humankind\'s critical challenges in mental health, physical wellness, food scarcity, and nutrition. Through a proprietary bio-manufacturing platform, CB Therapeutics harnesses yeast, precision fermentation, and advanced genetic engineering to produce high-value molecules sustainably and cost-effectively. The company\'s 16,000 sq. ft. fully licensed facility in Southern California boasts cutting-edge laboratories, robust bioreactor systems, data generation for AI training applications, and an extensive suite of analytical instruments-enabling the delivery of transformative solutions in psychedelics, cannabinoids, food technologies, and more.SOURCE: CB Therapeutics

Analysis and Review: Pressure Infusion Bags Market by Product - (Reusable Pressure Infusion Bags and Disposable Pressure Infusion Bags), by Material (Nylon, Polyurethane, Latex, and Others), By Capacity (500cc, 1000cc, 3000cc, and above 3000cc), By Application- (Blood & Drug Infusion and Invasive Pressure Monitoring Procedure), by Indication (Trauma-Induced Haemorrhage, Obstetric Haemorrhage and Coagulopathy during cardiopulmonary bypass ), By End User (Hospitals, Specialized Clinics, Ambulatory Surgical Centers, Veterinary Hospitals, and Veterinary Clinics), and by Region- Forecast for 2025 - 2035 NEWARK, DE / ACCESSWIRE / December 30, 2024 / The global pressure infusion bags market is poised for significant expansion, with sales projected to grow from USD 388.2 million in 2025 to an impressive USD 707.7 million by 2035. The market is expected to achieve a compound annual growth rate (CAGR) of 6.2% during the forecast period from 2025 to 2035, driven by increasing demand across hospitals, clinics, and emergency care settings. Revenue in 2024 stood at USD 360.3 million, marking a strong foundation for this growth trajectory.The measurement of continuous beat to beat blood pressure by a pressure infuser coupled with other monitoring devices is an invasive method that is widely used by physicians. Major fluids in rapid infusion includes blood, blood products, blood expanders and intravenous solution. Certain factors that are driving the pressure infusion bags market growth include rapid infusion of blood and drugs that are necessary for patients suffering from trauma-induced haemorrhage, postpartum haemorrhage, and cardiac surgery. An increase in the number of transfusion and emergency cases account for the rise in demand for pressure infusion bags.Likewise, the rising prevalence of chronic diseases, surge in emergency transfusion cases, technological advancements and increasing R&D initiatives anticipates the market growth. The growing cases of blood transfusion in emergencies, coupled with the growing geriatric & immunocompromised population account for the increase in demand for pressure infusion bags.Globally, the burden of cancer incidence and mortality are rapidly growing among the growing population. The high prevalence reflects increase in both ageing and growth of the population, as well as changes in the prevalence and distribution of the main risk factors for cancer, associated with socio-economic development.Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trendshttps://www.futuremarketinsights.com/reports/pressure-infusion-bags-marketKey Drivers of Market Growth:Pressure infusion bags play a critical role in the healthcare sector, enabling the rapid and controlled administration of blood, medications, and intravenous fluids. These devices are indispensable in emergency care, particularly during invasive procedures that require precise fluid delivery.The market's growth is fueled by several factors:Rising Prevalence of Chronic Diseases:The increasing incidence of chronic diseases, including cancer, cardiovascular disorders, and trauma-related conditions, has driven a surge in demand for infusion devices. Pressure infusion bags are crucial in managing these conditions, particularly in intensive care units (ICUs).Surge in Surgical and Emergency Procedures:The growing volume of surgeries and emergency interventions has heightened the need for efficient infusion solutions. Pressure infusion bags ensure the accurate delivery of fluids under required pressure, reducing complications during medical procedures.Essential Role in Blood Transfusions and Invasive Monitoring:The use of pressure infusion bags in blood transfusions and invasive pressure monitoring has become a standard practice, further solidifying their position as essential medical devices.Market Outlook:The global healthcare industry continues to prioritize patient safety and procedural efficiency, which bodes well for the adoption of pressure infusion bags. Technological advancements and the increasing availability of these devices in emerging markets are expected to further bolster growth.As healthcare systems worldwide grapple with the challenges of rising chronic diseases and trauma cases, pressure infusion bags remain a vital component in ensuring effective and timely patient care.The pressure infusion bags market is on a promising growth path, driven by advancements in medical care and increasing global healthcare needs. With the market anticipated to reach USD 707.7 million by 2035, stakeholders in the healthcare sector have a significant opportunity to address growing demands and improve patient outcomes."The Pressure Infusion Bags Market is witnessing steady growth, driven by advancements in healthcare and rising demand for efficient fluid administration solutions."- saysSabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)Key Takeaways:Market Growth:The global pressure infusion bag market is projected to grow significantly, from USD 360.3 million in 2024 to USD 707.7 million by 2035, at a CAGR of 6.2% during the forecast period (2025-2035).The market value in 2025 is estimated to reach USD 388.2 million.Regional Insights:Canada: Expected to achieve a 7.4% CAGR from 2025 to 2035, reflecting robust growth in North America.Brazil: Anticipated to grow at a 4.3% CAGR, showing steady expansion in South America.France: Forecast to grow at a 4.5% CAGR, indicating moderate growth in the European market.Russia: Predicted to see a 6.9% CAGR, highlighting strong demand in Eastern Europe.Japan: Leading regional growth with the highest 7.9% CAGR in the Asia-Pacific market.South Korea: Estimated to grow at a 6.2% CAGR, underscoring consistent market expansion in the region.Spain: Projected to achieve a 7.2% CAGR, showcasing strong performance in Southern Europe.These growth trends highlight significant opportunities across various global markets, driven by rising demand and innovations in pressure infusion bag technology.Which Factors Are Restraining the Demand for Pressure Infusion Bags?The restraints for the global pressure infusion bags market include pressure on pricing, lack of specialized personnel, and lack of awareness of handling the blood products. As the pressure infusion bags space is a fairly fragmented market, and also due to the high volume & low-value nature of the markets, the prominent players are actively focusing on strengthening inorganic growth. The competition among manufacturers from China is driving the price down owing to the availability of low-cost labour as compared to other countries manufacturing cost.Even if many countries have programs for expansion and education for infusion therapy, lack of awareness and proper training to the clinicians and nursing staff affect the use of pressure infusion bags. Pressure infusion bags which are mostly used to minimize the chances of cross-contamination during fluid infusion process, makes them an effective tools to ensure patient's safety. An increase in awareness about patient safety is also a boon for the entire pressure infusion bags market. There have been many concerns raised against the high incidence of critical incidents which are related to the devices. The great number of these incidents have been reported to the Medical Devices Agency (which is now a part of Medicines and Healthcare products Regulatory Agency (MHRA)) and most of these incidents is considered to be attributable to human error.Additionally, lack of skilled professionals and occurrence of complications can be attributed to the misuse of the device, such as incorrect calibration or interpretation of the pressure display, etc. High incidence of long term complications associated with invasive arterial blood pressure monitoring has also been reported. Thus, the reliability and reproducibility of this instrument are highly dependent on skilled technicians or operators who interpret the results of pressure monitoring devices.Old Report Source:https://www.globenewswire.com/news-release/2019/09/12/1914777/0/en/Pressure-Infusion-Bags-Market-is-expected-to-grow-at-a-CAGR-of-6-during-2019-to-2029-Future-Market-Insights.htmlCompetitive Landscape:The pressure infusion bags market is witnessing significant investments aimed at acquisitions and strategic expansion to drive growth and enhance market presence. Companies are actively acquiring innovative technologies and products to diversify their offerings while forming strategic partnerships to broaden their global reach.Recent Industry Developments in the Pressure Infusion Bags Market:January 2022: ICU Medical Inc. successfully acquired Smiths Medical from Smiths Group PLC. This acquisition included a portfolio of syringe and ambulatory infusion devices, vascular access products, and essential care solutions.Vyaire Medical Inc., a global leader in medical technology, has reinforced its presence in the infusion therapy market. Renowned for its expertise in respiratory care and precision-engineered medical devices, the company continues to focus on delivering high-quality solutions tailored to critical patient care needs.Key Players of Pressure Infusion Bags Industry:Vyaire Medical Inc.VBM Medizintechnik GmbHMerit Medical Systems, Inc.Salter LabsAirLifeSmiths Medical, Inc.Statcorp MedicalSpengler SASRudolf Riester GmbHFriedrich Bosch GmbH & Co. KGKey Segments of Pressure Infusion Bags Industry:By Product:In terms of product, the industry is divided into disposable pressure infusion bags and reusable pressure infusion bags.By Capacity:In terms of capacity, the industry is segregated into 500cc, 1000cc, 3000cc and above 3000cc.By Material:In terms of material, the industry is segregated into nylon, polyurethane, latex and others.By Application:In terms of application, the industry is segregated into blood & drug infusion and invasive pressure monitoring procedure.By Indication:In terms of indication, the industry is segregated into trauma induced hemorrhage, obstetric hemorrhage and coagulopathy during cardiopulmonary bypass.By End-User:The industry is classified by end user as hospitals, outpatient facilities, clinics and long-term centers.By Region:Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East & Africa have been covered in the report.Author By:Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain:The global sales of intraosseous infusion devices are estimated to be worth USD 5,065.8 million in 2025 and anticipated to reach a value of USD 10,463.8 million by 2035. Sales are projected to rise at a CAGR of 7.5% over the forecast period between 2025 and 2035.The pressure infusion cuffs market size is estimated to ascend at a valuation of approximately USD 350.8 million by 2024 as per Future Market Insights report. The change in industry valuation for the pressure infusion cuffs is likely to be at a moderate CAGR of 5.7% through 2034. The change in value in the ecosystem is estimated to reach a value of USD 610.7 million by the end of the forecast period.The advanced infusion system market share is projected to be valued at USD 8,862.8 million in 2023 and is expected to rise to USD 16,536.9 million by 2033. The sales of advanced infusion systems are expected to record a significant CAGR of 6.4% during the forecast period.The global IV infusion gravity bags market demand garnered a market value of USD 723.8 Million in 2022 and is expected to accumulate a market value of USD 1281.3 Million by registering a CAGR of 5.87% in the forecast period 2022 to 2032.The global allergy treatment market growth is estimated to account for USD 22.8 billion in 2024. It is anticipated to grow at a CAGR of 7.2% during the assessment period and reach a value of USD 42.7 billion by 2034.The global nephelometry market strategies are estimated to be worth USD 1,220.5 million in 2024 and are anticipated to reach a value of USD 2,288.9 million by 2034. Sales are projected to rise at a CAGR of 6.3% over the forecast period between 2024 and 2034.The depression treatment market outlook is valued at USD 11 billion in 2024. It is anticipated to grow at a CAGR of 5.2% during the assessment period and reach a value of USD 18.3 billion by 2034.The USA compounding pharmacies market overview is estimated to reach USD 5,156.2 million in 2024. It is estimated that revenue will increase at a CAGR of 7.8% between 2024 and 2034. The industry is anticipated to reach USD 10,659.3 million by 2034.The companion animal drugs market opportunity is estimated to reach USD 16,131.2 million in 2024. It is estimated that revenue will increase at a CAGR of 6.2% between 2024 and 2034. The industry is anticipated to reach USD 29,329.2 million by 2034.The global cancer diagnostics market trends are estimated to be worth USD 60.4 billion in 2024 and anticipated to reach a value of USD 136.7 billion by 2034. Sales are projected to rise at a CAGR of 8.5% over the forecast period between 2024 and 2034.About Future Market Insights (FMI)Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.Contact Us:Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USAT: +1-347-918-3531For Sales Enquiries: [email protected]Website:https://www.futuremarketinsights.comLinkedIn | Twitter | Blogs | YouTubeSOURCE: Future Market Insights, Inc.

Tailored solutions can bridge critical gaps in clinical research and medical device design, driving equity for women and diverse populations. For too long, the medical device industry has taken a one-size-fits-all approach to innovation, often neglecting the anatomical and physiological nuances of women and other underrepresented groups. One of the many roots of this disparity runs back to the thalidomide tragedy of the 1960s, in which a morning sickness drug was linked to birth defects. Following public outcry, the FDA excluded women of childbearing age from clinical trials. This exclusion lingered for two decades, during which the majority of clinical research was conducted on male subjects, creating a systemic gap in data and understanding of women’s unique health needs​. Against this backdrop, leaders from across the medical device industry gathered at DeviceTalks West to discuss how the industry is tackling these inequities head-on. Panelists included Dr. Jennifer Jones-McMeans, divisional VP of global clinical affairs at Abbott Vascular, who has pioneered efforts to enhance diversity in clinical trials; Hexagon Health CEO Dr. Shirin Towfigh, one of the few female hernia surgeons in the U.S., whose patented innovations are reshaping hernia repair; and Frontline Medical Technologies co-founder and CEO Dr. Asha Parekh, whose engineering expertise has driven the development of devices for critical care applications with specific focus on women’s anatomies. Overcoming historical oversights in clinical trials The historical lack of women in clinical trials has far-reaching consequences and has led to missed opportunities for improving care across all populations. “Women present differently with cardiovascular disease symptoms. Their arteries are smaller, and their needs are often overlooked in design,” said Jones-McMeans. Towfigh shared a particularly egregious example from her field. In hernia research, women were almost entirely excluded. “There’s been about seven prospective randomized clinical trials for inguinal hernias. Over 10,000 patients enrolled, a total of 17 women. Only one of those trials had women. All the rest had zero,” she said. “That alone skews industry standards, skews what industry sees as how to design.” This imbalance not only skews device performance data but also outcomes. “The female pelvis is different, yet female patients are often misdiagnosed or underserved because the designs don’t reflect their needs,” Towfigh said. Her patented hernia mesh redesigns aim to bridge this gap, reducing complications like chronic pain and dysfunction. Parekh noted that while addressing the unique needs of women often highlights critical gaps in clinical trials, these innovations can ultimately benefit all patients. “Our device is an aortic occlusion device, used specifically for postpartum hemorrhage,” she said. “Women have smaller arteries and pregnant women are susceptible to being hypercoagulable, so thrombosis is an issue. [But] it’s not just women in these emergency scenarios — men come into the emergency room too.” To address these challenges, Parekh designed with these considerations in mind from the very beginning, prioritizing a smaller, minimally invasive device. “We’re all trying to miniaturize minimally invasive [devices], everything as small and unobstructed as possible,” she said. Starting with a focus on specific populations like women ensures that devices are better suited for all patients in the long run. The role of representation in medical device design Inclusive medical device design begins with diverse voices at the table. As one of the few female hernia surgeons, Towfigh said her practice sees a disproportionate number of female patients. This exposure gives her a unique lens to identify trends and unmet needs in her field. “If I wasn’t here, who would notice these patterns?” she asked. Parekh echoed the sentiment, saying, “Whether it’s engineers, clinicians, or trial participants, representation matters at every stage of development. You can’t design for a population you don’t truly understand.” Abbott’s approach, as described by Jones-McMeans, involves both top-down and grassroots strategies. Abbott is intentionally recruiting more women for leadership roles in clinical trials and as investigators at clinical site, and made a concerted effort to ensure gender parity among study participants. “We’ve partnered with organizations like Women as One to support female physicians and MedtechWomen to promote inclusivity,” she said. “Internally, we created a diversity and research office to ensure these priorities are embedded across our clinical trials.” Investment in inclusive innovation Funding remains a significant barrier to advancing gender-sensitive medical device design. Historically, investors have hesitated to fund devices tailored to smaller patient populations, often viewing them as niche markets. But this mindset is shifting. ”Many investors are simply unaware of the market opportunity until you present the data,” Parekh said, emphasizing the importance of using clinical and market data to build a compelling case during funding pitches. Towfigh’s solution has been to self-fund her innovations, which isn’t always an option. “It’s tough because you have to convince industry to invest money in a niche product … for a small proportion” of the population, she said. Beyond gender and toward truly inclusive innovation While much of the discussion focused on women, the broader goal is designing for diverse anatomies. “Whether it’s pediatric patients, underserved ethnic groups, or individuals with unique physiological needs, personalized medicine is the future,” Parekh said. Inclusive innovation — whether addressing women’s cardiovascular needs or designing for pediatric patients — has far-reaching benefits. But it won’t be achieved overnight, as systemic change takes sustained effort and collaboration. “It’s a long game,” Jones-McMeans said. “The efforts we’re putting in now may not bear fruit until decades down the line. But maybe in 30 years, there’s a different group of women sitting here talking about the fruits of the work we’re doing today.” Parekh was optimistic, given the growing momentum behind inclusive medical device design. ”I think we have come such a long way in terms of moving things forward for not just women but for diverse anatomies,” she said. Towfigh shared in the optimism, emphasizing that progress comes through persistence and building a solid foundation of data. “You just have to keep pushing,” she said. “It takes time. People need to start hearing it over and over and over again, and you have to persist.”